

**Abstract Submission No. : 2023**

## **A mitochondrial cardiolipin targeting peptide ameliorates acute kidney oxidative damage**

**Soie Kwon**<sup>1</sup>, Hyuk Huh<sup>1</sup>, Kyu Hong Kim<sup>3</sup>, Jong Joo Moon<sup>3</sup>, Kyung Don Yoo<sup>2</sup>, Yon Su Kim<sup>1</sup>, Seung Hee Yang<sup>3</sup>

<sup>1</sup>Department of Internal Medicine-Nephrology, Seoul National University Hospital, Korea, Republic of

<sup>2</sup>Department of Internal Medicine-Nephrology, Ulsan University Hospital, Korea, Republic of

<sup>3</sup>Department of Department of Kidney Research Institute, Seoul National University College of Medicine, Korea, Republic of

**Objectives:** Mitochondria is a major organelle of adenosine triphosphate production and O<sub>2</sub> consumption. Also, kidney is mitochondria abundant organ. In this respect, many mitochondria-targeting agents were developed, although there is no single agent approved in clinical practice. We investigate renoprotective effect of newly invented mitochondrial cardiolipin targeting peptide, the SNU-RD, in hypoxic condition.

**Methods:** Based on our experience that dimer formation by bisulfate bond of cell penetrating peptide accelerate cell permeability, we synthesized 15 candidate tetra-peptides which target inner mitochondrial membrane specific phospholipid, the cardiolipin. After cell viability, distribution and mitochondrial functional test, we selected best candidate and tentatively named as SNU-RD. As hypoxic damage, bilateral ischemia-reperfusion injury (IRI) and primary cultured human proximal tubular epithelial cells (hPTECs) with H<sub>2</sub>O<sub>2</sub> were chosen. Wild-type mice were divided into four groups: sham, IRI, IRI with low dose or high dose SNU-RD. After SNU-RD treatment with various concentration (10nM, 100nM, 1000nM), high dose H<sub>2</sub>O<sub>2</sub> stress was done. Mitochondrial function was tested and mitochondrial oxygen consumption rate (OCR) was measured.

**Results:** In IRI, serum BUN and creatinine were significantly decreased without SNU-RD dose dependency. Pathologic findings (NGAL and cytochrome C expression) were improved. Also, mitochondrial anti-oxidative enzyme (NQO-1, SOD-1), ATP6 and IL-10 mRNAs were over-expressed after SNU-RD treatment.

Cell viability was increased and both early and late apoptosis were decreased dose-dependently. IL-1 $\beta$ , IL-18, p16 and p21 mRNA were dramatically down-regulated. When traced by rhodamine, SNU-RD was intensively distributed to mitochondria then cytoplasm. In JC-1 assay, ratio of healthy mitochondria was increased with SNU-RD. Basal and maximal OCR were most recovered from SNU-RD 10nM.


**Conclusions:** Mitochondrial cardiolipin targeting peptide, SNU-RD can be a treatment choice of acute kidney injury by restoring mitochondrial function.

Figure 1. SNU-RD effect on mitochondria

# KSN 2021

## FULLY VIRTUAL MEETING

September 02 (Thu) - 05 (Sun)



(A, B) Rhodamine tagged SNU-RD concentrated intensively to mitochondria, (C) Increased proportion of healthy mitochondria after SNU-RD treatment in JC-1 assay, (D-E) Treatment of SNU-RD 10nM effectively restore mitochondrial function from hypoxic injury